David Kendall

David Kendall

Chief Tech/Sci/R&D Officer at ZEALAND PHARMA A/S

Net worth: 836 257 $ as of 28/02/2026

64 year
Health Technology
Consumer Services
Commercial Services

Profile

David M.
Kendall
currently works at Zealand Pharma A, as Chief Medical Officer from 2022.
Dr. Kendall also formerly worked at Amylin Pharmaceuticals, Inc., as Medical Director from 2005 to 2008, Park Nicollet Health Services, as Director & Medical Director from 1994 to 1997, International Diabetes Center, as Medical Director from 1997 to 2009, Eli Lilly & Co., as Vice President-Global Medical Affairs from 2011 to 2018, MannKind Corp., as Chief Medical Officer from 2018 to 2020, American Diabetes Association, as Chief Scientific & Medical Affairs Officer from 2009 to 2011, and Lilly Diabetes, as Vice President-Global Medical Affairs from 2011 to 2018.
Dr. Kendall received his undergraduate degree in 1983 from St. Olaf College and doctorate degree in 1988 from the University of Minnesota.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
31/12/2025 14,546 ( 0.02% ) 836 257 $ 28/02/2026

David Kendall active positions

CompaniesPositionStart
ZEALAND PHARMA A/S Chief Tech/Sci/R&D Officer 02/06/2022

Former positions of David Kendall

CompaniesPositionEnd
MANNKIND CORPORATION Chief Tech/Sci/R&D Officer 28/08/2020
ELI LILLY AND COMPANY Corporate Officer/Principal 01/02/2018
Lilly Diabetes
Corporate Officer/Principal 01/01/2018
Chief Tech/Sci/R&D Officer 01/07/2011
Chief Tech/Sci/R&D Officer 01/09/2009
See the detail of David Kendall's experience

Training of David Kendall

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

86

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Commercial Services

Health Services

Commercial Services

Lilly Diabetes